Suppr超能文献

β3肾上腺素能受体参与奈必洛尔诱导的大鼠主动脉血管舒张作用。

Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta.

作者信息

de Groot Annemieke A, Mathy Marie-Jeanne, van Zwieten Pieter A, Peters Stephan L M

机构信息

Department of Pharmacology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.

出版信息

J Cardiovasc Pharmacol. 2003 Aug;42(2):232-6. doi: 10.1097/00005344-200308000-00012.

Abstract

Nebivolol is a highly selective beta(1) adrenoceptor blocker with additional vasodilating properties. Although it has been shown that the nebivolol-induced vasorelaxation is nitric oxide (NO) and cGMP dependent, the receptor that mediates these actions remains controversial, and serotonergic as well as beta-adrenergic pathways may be involved. Therefore, functional experiments investigating the receptor involved in nebivolol-induced vasorelaxation were performed in the rat aorta. Isolated aortic rings were exposed to cumulative concentrations of nebivolol. Nebivolol concentrations of 3 micromol/L and higher caused vasorelaxation, which was inhibited by the presence of the NO synthase inhibitor l-NNA (100 micromol/L), or by mechanical removal of the endothelium. Exposure of the vessel rings to the selective 5-HT(1A) antagonist NAN-190 (1 micromol/L) or the 5-HT(1/2) antagonist methysergide (1 micromol/L) did not influence nebivolol-induced vasorelaxation. Similarly, the incubation with the beta(2)-adrenoceptor antagonist butoxamine (50 micromol/L) did not prevent vasorelaxation. The selective beta(3)-adrenoceptor antagonist S-(-)-cyanopindolol (1 micromol/L), however, significantly counteracted the nebivolol-induced vasorelaxation. Furthermore, exposure of the aortic rings to cumulative concentrations of the beta(3) selective adrenoceptor agonist BRL37344 caused, like nebivolol, NO-dependent vasorelaxation that was antagonized by S-(-)-cyanopindolol. The results suggest that nebivolol-induced NO-dependent vasorelaxation is, at least in part, caused by a beta(3)-adrenoceptor agonistic effect.

摘要

奈必洛尔是一种具有额外血管舒张特性的高选择性β(1)肾上腺素能受体阻滞剂。尽管已表明奈必洛尔诱导的血管舒张是一氧化氮(NO)和环磷酸鸟苷(cGMP)依赖性的,但介导这些作用的受体仍存在争议,且可能涉及5-羟色胺能以及β-肾上腺素能途径。因此,在大鼠主动脉中进行了研究参与奈必洛尔诱导血管舒张的受体的功能实验。将离体主动脉环暴露于累积浓度的奈必洛尔。3微摩尔/升及更高浓度的奈必洛尔引起血管舒张,这被NO合酶抑制剂L-NNA(100微摩尔/升)的存在或通过机械去除内皮所抑制。将血管环暴露于选择性5-HT(1A)拮抗剂NAN-190(1微摩尔/升)或5-HT(1/2)拮抗剂美西麦角(1微摩尔/升)并不影响奈必洛尔诱导的血管舒张。同样,与β(2)-肾上腺素能受体拮抗剂布托沙明(50微摩尔/升)孵育也不能阻止血管舒张。然而,选择性β(3)-肾上腺素能受体拮抗剂S-(-)-氰吲哚洛尔(1微摩尔/升)显著对抗了奈必洛尔诱导的血管舒张。此外,将主动脉环暴露于累积浓度的β(3)选择性肾上腺素能受体激动剂BRL37344,与奈必洛尔一样,引起了被S-(-)-氰吲哚洛尔拮抗的NO依赖性血管舒张。结果表明,奈必洛尔诱导的NO依赖性血管舒张至少部分是由β(3)-肾上腺素能受体激动效应引起的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验